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Research Letter | Obstetrics and Gynecology
Association of Past Chlamydia trachomatis Infection With Miscarriage
Andrew W. Horne, PhD; Nick Wheelhouse, PhD; Patrick J. Horner, MD; W. Colin Duncan, MD
Introduction
First-trimester miscarriages are commonly associated with chromosomal abnormality of the embryo
(approximately 50% of cases).1 However, 15% of first-trimester and 66% of second-trimester
miscarriages are attributed to reproductive tract infections.2 It has been suggested that Chlamydia
trachomatis is a causative organism, but its association with miscarriage is inconsistently reported.2-4
This difference of opinion likely reflects the poor performance of major outer membrane protein
(MOMP) peptide-based serology assays and the inability of nucleic acid amplification tests (which
detect current infection) to detect previous exposure.5 It is now possible to accurately measure
lifetime exposure to C trachomatis using an enzyme-linked immunosorbent assay (ELISA) that
detects antibodies to the chlamydial plasmid-encoded protein Pgp3.5 This ELISA is more sensitive
(73.8%) and specific (97.6%) than commercial ELISAs, including the Medac MOMP-peptide ELISA, or
previous serological antibody tests.5 Pgp3 is unique to C trachomatis, eliminating cross-reactivity
with antibodies to C pneumoniae infection (a common respiratory pathogen), a major weakness of
previous serological tests. The aim of this study was to provide an estimation of the association of
previous C trachomatis infection with the risk of spontaneous first-trimester miscarriage.
Methods
We performed a case-control study, recruiting women with ultrasonography confirming absence of a
fetal heart in the first trimester of pregnancy (miscarriage group) and women with normal
pregnancies that had progressed into the third trimester (control group) from the same catchment
population. Women with a past history of miscarriage were excluded from the control group.
Participants were identified from the Pregnancy Support Unit and Delivery Suite at the Royal
Infirmary of Edinburgh (a large UK National Health Service teaching hospital). The first study
participant was recruited on January 22, 2013, and the last participant was recruited on September
26, 2019. The Scotland A Research Ethics Committee approved this study, and written informed
consent was obtained from all participants. This study followed the Strengthening the Reporting of




P valueaControls (n = 118) Miscarriage group (n = 251)
Age, median (95% CI), y 34 (32-35) 33 (32-35) .72
BMI, mean (95% CI) 26.0 (25.0-27.0) 25.6 (24.9-26.3) .55
Self-reported past C trachomatis
infection, No. (%)
2 (1.7) 34 (13.5) <.001
C trachomatis seropositivity 33 (28.0) 65 (25.9) .71
Prior miscarriage NA 106 (41.4) NA
Prior live births 85 (72.0) 127 (50.6) <.001
History of smoking
Never 75 (66.4)b 165 (66.8)c >.99
Ex-smoker 27 (23.9)b 60 (24.3)c >.99
Smoker 11 (9.7)b 22 (8.9)c .84
Abbreviations: BMI, body mass index (calculated as
weight in kilograms divided by height in meters
squared); C trachomatis, Chlamydia trachomatis; NA,
not applicable.
a P < .05 indicates statistical significance.
b 113 responses.
c 247 responses.
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We anticipated a C trachomatis seroprevalence of 15% in women with miscarriage and 7% in the
control group on the basis of literature review3 and pilot work. Our proposed sample size (200 cases
and 100 controls) had greater than 95% power, with a level of significance (α) of .05 to estimate a
doubling of the C trachomatis–population attributable risk for miscarriage. We collected serum
samples and self-taken vulvovaginal swabs taken from 2 to 3 inches within the vagina for C
trachomatis nucleic acid amplification testing to detect current infection. Statistical analyses were
conducted using GraphPad Prism, version 8.0 (GraphPad). Analysis was by 2-tailed Fisher exact test,
and P < .05 indicated significance.
Results
A total of 251 women (median [95% CI] age, 33 [32-35] years) were included in the miscarriage group,
and 118 were included in the control group (median [95% CI] age, 34 [32-35] years). The groups were
well balanced for all characteristics measured at baseline (Table). A total of 65 women (25.9%; 95%
CI, 20.6%-31.4%) in the miscarriage group and 33 women (28.0%; 95% CI, 19.9%-36.1%) in the
control group had positive test results for Pgp3 antibodies, suggesting previous infection with C
trachomatis (P = .71). There was no evidence of active C trachomatis infection in either group. More
women in the miscarriage group (n = 34 [13.5%; 95% CI, 11.3%-15.7%]) than the control group (n = 2
[1.7%; 95% CI, 0.5%-2.9%]) self-reported past C trachomatis infection (P < .001).
Discussion
Contrary to the study by Baud et al,3 which was conducted on a similar-sized data set using a MOMP-
peptide ELISA, the present study, using the more sensitive Pgp3 ELISA, found no significant
association of past C trachomatis exposure with spontaneous first-trimester miscarriage. The lack of
genetic analysis of the miscarriages and inability to match for past obstetric history are limitations
of the study. It is unclear why more women in the miscarriage group self-reported C trachomatis
infection, as recall bias is unlikely to explain such a difference. One possibility is that women in the
miscarriage group were more likely to have had symptomatic C trachomatis infection and therefore
seek testing. However, the seroprevalence rates of over 25% observed in both cohorts suggest that
the prevalence of C trachomatis infection in young women—and the potential clinical outcomes of
other reproductive disorders, such as female infertility and ectopic pregnancy—remain
underestimated.
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